Webinar – Analysis Group Senior Advisor Genia Long to Present on Costs, Benefits, and Savings of New Drug Treatments
Event:Health Care Coverage Challenges: New Treatments With High Upfront Costs, Long-term Benefits and Delayed Savings
Date: March 29, 2018
Host:National Pharmaceutical Council (NPC)
Times:12:30–1:30 p.m. (PT) / 3:30–4:30 p.m. (ET)
Analysis Group Senior Advisor Genia Long will present research results to an NPC-moderated panel exploring the challenges posed by new drug treatments such as gene therapy that have significant upfront costs but whose curative effects result in long-term benefits. Her presentation – based on a paper in the American Journal of Managed Care with Harvard University Professor David Cutler, Analysis Group Vice President Noam Kirson, and NPC coauthors – explores whether such therapies will exhibit heightened disconnects between short-term budget impact and long-term costs and benefits, and whether creative payment models will be necessary to address gaps among the impacts on initial payers, downstream payers, and society in order to assure appropriate patient access.